Top broker slaps $46.50 price target on Sirtex Medical Limited shares

Can the Sirtex Medical Limited (ASX:SRX) share price rocker higher in 2016?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Innovative cancer treatment business Sirtex Medical Limited (ASX: SRX) slightly disappointed the market last week after reporting dose sales of its SIR-spheres treatment grew just 15.7% over the prior corresponding half.

The company was coming off a strong comparative period and the undoubted highlight from the overall result was an especially strong performance in its core North American market that delivered dose sales growth of 18.8%, while Europe and Asia disappointed with single-digit growth below expectations.

The company also enjoyed the twin benefits of a plunging Aussie dollar and price increases over the period to produce a whopping 47% increase in interim profit to $23.9 million.

However, the stock was sold off on the result presumably because the total dose sales growth of 15.7% meant prior guidance from the CEO for full year growth of at least 19.7% looks a tough ask, unless the company produces a stellar second half.

However, the CEO Gilman Wong must still be confident of some exceptional growth over the current period having reaffirmed dose sales growth guidance at February's results announcement.

One big boost for the sales push is the publication of positive news around the clinical benefits of the company's products in the prestigious Journal of Clinical Oncology. Sirtex believes the endorsement in a world-leading medical journal should assist sales efforts into the second half of the financial year.

Several analysts also remain bullish on the business including broker Wilson HTM, which slapped a $46.50 price target on the stock and stated that potential catalysts ahead include the SARAH clinical trial results and dose sales price growth.

Another stock rocketing higher today in the biotech space is regenerative medicine specialist Mesoblast limited (ASX: MSB).

Its big price moves coming on the back of a positive announcement regarding trial results for one of its regenerative medicine products used in children suffering from acute Graft Versus Host Disease (aGVHD). It has also just launched its GVHD regenerative medicine product for commercial sale in Japan.

Motley Fool contributor Tom Richardson owns shares of Sirtex Medical Limited. You can find Tom on Twitter @tommyr345 Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »